Walgreens Boots Alliance — Q4 2023 Earnings Presentation
51 slides from Walgreens Boots Alliance's earnings presentation, Oct 12, 2023
Slide 1: Fourth Quarter and Fiscal 2023 Results
Fourth Quarter and Fiscal 2023 Results October 12, 2023 © 2023 Walgreens Boots Alliance, Inc. All rights reserved.
Slide 2: Safe Harbor and Non-GAAP
Safe Harbor and Non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in this presentation that are not historical are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitat
Slide 3: Focus on Execution
Focus on Execution Ginger Graham Interim Chief Executive Officer, WBA © 2023 Walgreens Boots Alliance, Inc. All rights reserved. 3
Slide 4: Strong focus on execution to stabilize performance
Strong focus on execution to stabilize performance • Tim Wentworth appointed Chief Executive Officer, effective October 23rd • Near-term operational priorities representing value creation opportunities − Prioritization of customer-centered investments to support our stores and drive sales growth − S
Slide 5: 4Q & FY23 Results
4Q & FY23 Results Manmohan Mahajan Interim Global Chief Financial Officer, WBA © 2023 Walgreens Boots Alliance, Inc. All rights reserved. 5
Slide 6: WBA 4Q23 Financial Highlights
Reported Fx Constant Fx 4Q23 $ in millions (except EPS) B/(W) vs. 4Q22 B/(W) vs. 4Q22 Sales $35,422 + 9.2% + 8.3% Operating Income GAAP ($450) + $371 WBA 4Q23 Adjusted $683 (8.3)% (9.8)% Financial Net Earnings GAAP ($180) + $235 Highlights Adjusted $575 (17.1)% (18.1)% EPS GAAP ($0.21) + $0.27 Adjus
Slide 7: WBA FY23 Financial Highlights
Reported Fx Constant Fx FY23 $ in millions (except EPS) B/(W) vs. FY22 B/(W) vs. FY22 Sales $139,081 + 4.8% + 5.6% Operating Income GAAP ($6,882) ($8,269) WBA FY23 Adjusted $3,871 (24.6)% (24.1)% Financial Net Earnings GAAP ($3,080) ($7,417) Highlights Adjusted $3,439 (21.1)% (20.5)% EPS GAAP ($3.57
Slide 8: U.S. Retail Pharmacy Financials
4Q23 B/(W) vs. 4Q22 FY23 B/(W) vs. FY22 $ in millions Sales $27,666 + 3.7% $110,314 + 1.1% Adj. gross profit $5,166 (4.6)% $22,309 (6.4)% Adj. SG&A % of sales 17.0% 0.9%p 17.3% 0.5%p U.S. Retail Adj. operating income $554 (29.4)% $3,689 (26.6)% Pharmacy Adj. operating margin1 1.6% (0.7)%p 2.9% (1.1)
Slide 9: U.S. Pharmacy
4Q23 4Q23 FY23 FY23 4Q23 vs. 4Q22 | FY23 vs. FY22 Total Comparable Total Comparable Pharmacy sales + 6.4% + 9.2% + 2.1% + 7.2% Prescriptions (0.5)% + 0.9% (0.4)% + 0.6% Prescriptions ex. + 0.2% + 1.6% + 1.4% + 2.5% Immunizations U.S. Pharmacy • Comp pharmacy sales +9.2% primarily due to brand inflat
Slide 10: U.S. Retail
4Q23 FY23 4Q23 vs. 4Q22 | FY23 vs. FY22 Total retail sales (4.3)% (1.6)% Comparable retail sales (3.3)% (0.8)% • 4Q comp retail sales (3.3)%, impacted by a weaker respiratory season and macro-driven U.S. Retail consumer pressure − Key headwinds: COVID-19 OTC test kits (~160 bps), cough cold flu (~10
Slide 11: International Financials
Constant Fx Constant Fx 4Q23 FY23 $ in millions B/(W) vs. 4Q22 B/(W) vs. FY22 Sales $5,784 + 6.7% $22,198 + 6.8% Adj. gross profit $1,284 + 9.9% $4,704 + 7.3% Adj. SG&A % of sales 17.7% + 0.7%p 17.0% + 0.7%p International Adj. operating income $259 + 52.2% $935 + 32.6% Financials Adj. operating marg
Slide 12: Boots UK Financials
4Q23 FY23 4Q23 vs. 4Q22 | FY23 vs. FY22 Pharmacy comp. sales + 9.9% + 3.9% Retail comp. sales + 11.7% + 12.5% Boots UK Financials • Strong retail comp sales growth of +11.7% in 4Q, with growth across all categories − Store footfall improved ~+4% vs. prior year − Continued growth in store basket size
Slide 13: U.S. Healthcare Financials
4Q23 B/(W) vs. 4Q22 FY23 B/(W) vs. FY22 $ in millions Sales $1,972 + $1,351 $6,570 + $4,774 Adj. gross profit $147 + $155 $414 + $408 Adj. SG&A ($230) ($87) ($980) ($604) U.S. Healthcare Adj. operating loss ($83) + $68 ($566) ($197) Financials Adj. EBITDA ($30) + $103 ($376) ($64) • 4Q sales of $2B
Slide 14: Cash Flow
B/(W) FY23 $ in millions- vs. FY22 Operating cash flow $2,258 ($1,641) Cash capital expenditure ($2,117) ($384) Acquisition-related payments $524 $524 Free cash flow $665 ($1,500) Cash Flow • Generated $2.3B in operating cash flow and $665M of free cash flow • Year over year operating cash flow adve
Slide 15: FY24 Guidance
FY24 Guidance Manmohan Mahajan Interim Global Chief Financial Officer, WBA © 2023 Walgreens Boots Alliance, Inc. All rights reserved. 15
Slide 16: Introducing FY24 guidance
Introducing FY24 guidance • FY24 adj. EPS guidance of $3.20-$3.50 vs. FY23 adj. EPS of $3.98 − Reflects lower sale and leaseback contribution, higher tax rate, and lower COVID-19 contribution − Excluding these headwinds, underlying growth expected to be driven by incremental cost savings and improvi
Slide 17: Underlying growth reflects cost discipline and improving profitability in U.S. Healthcare
Underlying growth reflects cost discipline and improving profitability in U.S. Healthcare $3.98 (13)-(11)% $3.98 (9)-(7)% $3.30- +9-12% (20)-(12)% $3.50 (7)-(6)% $3.20- $3.50 © 2023 Walgreens Boots Alliance, Inc. All rights reserved. Refer to safe harbor and non-GAAP on slide 2, endnotes on slide 32
Slide 18: WBA FY24 Guidance
WBA FY24 CFx % YOY Change Sales $141.0 - $145.0B +1% - +4% Adj. Op. Income $3.4 - $3.7B (12)% - (5)% WBA FY24 Adj. EPS $3.20 - $3.50 (20)% - (12)% Guidance Key Considerations: • Tailwinds: Cost savings, U.S. Healthcare scaling and profitability initiatives, U.S. pharmacy gross profit growth ex. COVI
Slide 19: U.S. Retail Pharmacy Guidance
U.S. Retail Pharmacy FY24 % YOY Change Sales $110.5 - $113.0B 0% - +2% Adj. Op. Income $3.2 - $3.4B (13)% - (8)% U.S. Retail Key Considerations: • Sales flat to slightly up, with top-line growth driven by pharmacy Pharmacy • Script volume primarily driven by market, adherence programs, and access Gu
Slide 20: International Guidance
International FY24 % YOY Change CFx % YOY Sales $22.5 - $23.5B +1% - +6% 0% - +4% Adj. Op. Income $745 - $770M (20)% - (18)% (21)% - (18)% International Guidance Key Considerations: • CFx sales growth of 0% - +4%, with all markets growing, partly offset by Chile business disposal • AOI decline refle
Slide 21: U.S. Healthcare Guidance
U.S. Healthcare FY24 YOY Change Sales $8.3 - $8.8B +$1.7 - $2.2B Adj. Op. Income $(320) - $(220)M +$250 - $350M Adj. EBITDA $(50) - $50M +$325 - $425M U.S. Healthcare Key Considerations: Guidance • Sales include full year contribution from Summit Health/CityMD • Pro forma sales +10-17%, including gr
Slide 22: FY24 corporate assumptions
FY24 corporate assumptions $ millions FY23 FY24 Comments • Lower non-recurring tax benefits Adj. Tax Rate 9.8% 19% - 20% • Higher international statutory tax rates Interest Expense $(580) $(510) - $(490) • Reflects lower debt balances • Impact of full year Summit transaction, EMI/NCI $340 $335 - $35
Slide 23: Benefits from cost savings and U.S. Healthcare have a muted impact in 1Q
Benefits from cost savings and U.S. Healthcare have a muted impact in 1Q, and are expected to scale over the balance of the year Key YOY headwinds with outsized 1Q impact Drivers of sequentially improving 2Q-4Q earnings profile 1Q 2023 adj. EPS $1.16 • Cost savings: Recent actions to improve cost ba
Slide 24: U.S. Healthcare
U.S. Healthcare John Driscoll EVP & President U.S. Healthcare Segment © 2023 Walgreens Boots Alliance, Inc. All rights reserved. 24
Slide 25: Investing in and scaling healthcare services, and building on the pharmacy foundation
Investing in and scaling healthcare services, and building on the pharmacy foundation Go To Market Specialty Clinical Trial Health Clients Served: Specialty Pharmacy Pharmacy Patients Health Payors Summit Health Providers & Health Systems Retail & Pharmacy Pharma & Aggregators Specialty Health Healt
Slide 26: U.S. Healthcare has scaled to nearly $8 billion in sales in two years
U.S. Healthcare has scaled to nearly $8 billion in sales in two years, now shifting focus to profitable growth U.S. Healthcare Annualized Reported Sales ($B) • VillageMD has quickly expanded, with legacy business achieving +46% pro forma sales growth in FY23, and Summit CareCentrix $7.9 Health acqui
Slide 27: VillageMD is reducing healthcare costs and growing membership in value-based arrangements
VillageMD is reducing healthcare costs and growing membership in value-based arrangements MA medical loss ratio member cohort progression shows ability to bend …while continuing to expand MA full risk membership the cost curve… Houston Georgia Arizona MA Full Risk Member Months Growth (FY22-FY23) 92
Slide 28: Pearl Health partnership accelerates WBA’s expansion into risk
Pearl Health partnership accelerates WBA’s expansion into risk • Walgreens will use Pearl Health’s tech platform and provider network to take on full risk for ~9,000 ACO REACH lives in 12 markets • Initial services through Walgreens Pharmacy and Walgreens Health, with future opportunities for wrapar
Slide 29: Closing Remarks
Closing Remarks Ginger Graham Interim Chief Executive Officer, WBA © 2023 Walgreens Boots Alliance, Inc. All rights reserved. 29
Slide 30: Strong focus on execution to stabilize performance
Strong focus on execution to stabilize performance • Prioritization of customer-centered investments to support our stores and drive sales growth • Swift decision making to realign our cost base, strictly evaluate all capital investments, and improve cash flow • Operational clarity to accelerate exe
Slide 31: Q&A
Q&A © 2023 Walgreens Boots Alliance, Inc. All rights reserved. 31
Slide 32: Endnotes
Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures • The Company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating
Slide 33: Appendix
Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente
Slide 34: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except net debt ratio and lease adjusted net debt ratio) The Company defines net debt ratio as net debt divided by adjusted earnings before interest, tax,
Slide 35: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET LOSS TO ADJUSTED OPERATING INCOME, ADJUSTED EBITDA and ADJUSTED EBITDAR Fiscal 2023 Net loss (GAAP) $ (3,528) Post-tax earnings from other equity metho
Slide 36: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Certain legal and regulatory accruals and settlements relate to significant charges associated with certain legal proceedings, including legal defense costs. The Compa
Slide 37: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except per share amounts) NET (LOSS) EARNINGS TO ADJUSTED NET EARNINGS AND DILUTED NET (LOSS) EARNINGS PER SHARE TO ADJUSTED DILUTED NET EARNINGS PER SHARE
Slide 38: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET (LOSS) EARNINGS TO ADJUSTED NET EARNINGS AND DILUTED NET (LOSS) EARNINGS PER SHARE TO ADJUSTED DILUTED NET EARNINGS PER SHARE Three months ended August
Slide 39: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except per share amounts) NET (LOSS) EARNINGS TO ADJUSTED NET EARNINGS AND DILUTED NET (LOSS) EARNINGS PER SHARE TO ADJUSTED DILUTED NET EARNINGS PER SHARE
Slide 40: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Certain legal and regulatory accruals and settlements relate to significant charges associated with certain legal proceedings, including legal defense costs. The Compa
Slide 41: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 16 Adjustments to post-tax earnings from other equity method investments consist of the proportionate share of certain equity method investees’ non-cash items or unusual
Slide 42: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended August 31, 2023 Walgreens Boots U.S. Retail Pharmacy 1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 27,666 $
Slide 43: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended August 31, 2022 Walgreens Boots U.S. Retail Pharmacy 1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 26,683 $
Slide 44: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Twelve months ended August 31, 2023 Walgreens Boots U.S. Retail Pharmacy 1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 110,314
Slide 45: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Twelve months ended August 31, 2022 Walgreens Boots U.S. Retail Pharmacy 1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 109,078
Slide 46: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) 1 Operating (loss) income for U.S. Retail Pharmacy includes equity earnings in Cencora. As a result of the two month reporting lag, operating loss for the
Slide 47: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) OPERATING LOSS TO ADJUSTED EBITDA FOR THE U.S. HEALTHCARE SEGMENT Three months ended August 31, Twelve months ended August 31, 2023 2022 2023 2022 1 Operat
Slide 48: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS IN CENCORA Three months ended August 31, Twelve months ended August 31, 2023 2022 2023 2022 Equity earnings in Cencora (GAAP) $ 65 $ 88 $ 2
Slide 49: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended August 31, 2023 Three months ended August 31, 2022 (Loss) earnings Income tax (Loss) earnings Income tax bef
Slide 50: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended August 31, Twelve months ended August 31, 2023 2022 2023 2022 Net cash provided by operating activities (GAAP) $ 1,039 $
Slide 51: Supplemental Financial Information
Supplemental Financial Information Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Supplemental sale-leaseback financial information Three months ended Twelve months ended August 31, 2023 Change vs. 4Q22 August 31, 2023 Change vs. FY22 U.S. Retail P
Walgreens Boots Alliance — Q4 2023 Earnings Presentation on 6ix